These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18977146)

  • 1. The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase.
    Ozawa T; Tsuji E; Ozawa M; Handa C; Mukaiyama H; Nishimura T; Kobayashi S; Okazaki K
    Bioorg Med Chem; 2008 Dec; 16(24):10311-8. PubMed ID: 18977146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase inhibitors and the case for CH...O hydrogen bonds in protein-ligand binding.
    Pierce AC; Sandretto KL; Bemis GW
    Proteins; 2002 Dec; 49(4):567-76. PubMed ID: 12402365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CH/pi hydrogen bonds determine the selectivity of the Src homology 2 domain to tyrosine phosphotyrosyl peptides: an ab initio fragment molecular orbital study.
    Ozawa T; Okazaki K
    J Comput Chem; 2008 Dec; 29(16):2656-66. PubMed ID: 18484636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of CH/π hydrogen bonds in recognition of the core motif in proline-recognition domains: an ab initio fragment molecular orbital study.
    Ozawa T; Okazaki K; Kitaura K
    J Comput Chem; 2011 Oct; 32(13):2774-82. PubMed ID: 21710635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
    Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
    J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CH/π hydrogen bonds play a role in ligand recognition and equilibrium between active and inactive states of the β2 adrenergic receptor: an ab initio fragment molecular orbital (FMO) study.
    Ozawa T; Okazaki K; Kitaura K
    Bioorg Med Chem; 2011 Sep; 19(17):5231-7. PubMed ID: 21820903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of human Fyn kinase domain complexed with staurosporine.
    Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
    Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantum mechanical study on phosphotyrosyl peptide binding to the SH2 domain of p56lck tyrosine kinase with insights into the biochemistry of intracellular signal transduction events.
    Pichierri F
    Biophys Chem; 2004 May; 109(2):295-304. PubMed ID: 15110947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.
    Tominaga Y; Jorgensen WL
    J Med Chem; 2004 May; 47(10):2534-49. PubMed ID: 15115396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contributions of NH...O and CH...O hydrogen bonds to the stability of beta-sheets in proteins.
    Scheiner S
    J Phys Chem B; 2006 Sep; 110(37):18670-9. PubMed ID: 16970498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.
    Pierce AC; ter Haar E; Binch HM; Kay DP; Patel SR; Li P
    J Med Chem; 2005 Feb; 48(4):1278-81. PubMed ID: 15715498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entry into a new class of protein kinase inhibitors by pseudo ring design.
    Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J
    Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.